Unicycive Therapeutics, Inc. (UNCY)
NASDAQ: UNCY · Real-Time Price · USD
7.17
-0.06 (-0.83%)
Apr 28, 2026, 4:00 PM EDT - Market closed
Unicycive Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Revenue | - | - | 0.68 | 0.95 | - | |
| Revenue Growth (YoY) | - | - | -29.02% | - | - | |
| Gross Profit | - | - | 0.68 | 0.95 | - | |
| Selling, General & Admin | 20.4 | 12.1 | 8.55 | 6.57 | 2.9 | |
| Research & Development | 9.12 | 20.01 | 12.9 | 12.44 | 6.08 | |
| Operating Expenses | 29.52 | 32.12 | 21.45 | 19 | 8.98 | |
| Operating Income | -29.52 | -32.12 | -20.77 | -18.05 | -8.98 | |
| Interest Expense | -0.07 | -0.07 | -0.08 | -0.01 | -0.63 | |
| Interest & Investment Income | 1.01 | 1.26 | 0.62 | - | - | |
| Other Non Operating Income (Expenses) | 2.02 | -5.8 | -10.3 | - | - | |
| EBT Excluding Unusual Items | -26.56 | -36.73 | -30.54 | -18.06 | -9.61 | |
| Other Unusual Items | - | - | - | - | -0.41 | |
| Pretax Income | -26.56 | -36.73 | -30.54 | -18.06 | -10.02 | |
| Net Income | -26.56 | -36.73 | -30.54 | -18.06 | -10.02 | |
| Preferred Dividends & Other Adjustments | - | 1.1 | 0.87 | - | - | |
| Net Income to Common | -26.56 | -37.82 | -31.41 | -18.06 | -10.02 | |
| Shares Outstanding (Basic) | 16 | 7 | 2 | 2 | 1 | |
| Shares Outstanding (Diluted) | 16 | 7 | 2 | 2 | 1 | |
| Shares Change (YoY) | 137.17% | 172.97% | 62.98% | 28.96% | 37.37% | |
| EPS (Basic) | -1.67 | -5.65 | -12.80 | -11.99 | -8.58 | |
| EPS (Diluted) | -1.67 | -5.65 | -12.80 | -11.99 | -8.58 | |
| Free Cash Flow | -31.34 | -28.65 | -18.3 | -15.65 | -5.8 | |
| Free Cash Flow Per Share | -1.97 | -4.28 | -7.46 | -10.40 | -4.96 | |
| Gross Margin | - | - | 100.00% | 100.00% | - | |
| Operating Margin | - | - | -3077.63% | -1898.21% | - | |
| Profit Margin | - | - | -4653.48% | -1898.84% | - | |
| Free Cash Flow Margin | - | - | -2710.37% | -1645.95% | - | |
| EBITDA | -29.48 | -32.1 | -20.77 | -18.05 | -8.98 | |
| D&A For EBITDA | 0.03 | 0.02 | 0.01 | 0.01 | 0 | |
| EBIT | -29.52 | -32.12 | -20.77 | -18.05 | -8.98 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.